Need professional-grade analysis? Visit stockanalysis.com
$741.68M
N/A
N/A
N/A
Sellas Life Sciences Group Inc (SLS) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $5.22, up 5.88% from the previous close.
Over the past year, SLS has traded between a low of $1.29 and a high of $5.54. The stock has gained 304.7% over this period. It is currently 5.8% below its 52-week high.
Sellas Life Sciences Group Inc has a market capitalization of $741.68M.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Side-by-side comparison against top Healthcare peers.